Stabilizing of cytokeratin in PLC/PRF/5 cells

中國醫藥大學機構典藏 China Medical University Repository, Taiwan > 醫學院 > 醫學系 > 期刊論文 > Item 310903500/30555

請使用永久網址來引用或連結此文件: http://ir.cmu.edu.tw/ir/handle/310903500/30555

題名:	Stabilizing of cytokeratin in PLC/PRF/5 cells
作者:	Su, B;Liu, YH;Pei, RJ;Yeh, CC;Yeh, KT;Lee, KY;Hsu, YH;Ho, CC;Lai, YS
貢獻者:	醫學院醫學系病理學科;China Med Coll, Dept Pathol, Sch Med, Taichung, Taiwan;China Med Coll Hosp, Dept Urol, Taichung, Taiwan;Changha Christian Hosp, Dept Pathol, Changhua, Taiwan;Jen Ai Hosp, Dept Pathol, Taichung, Taiwan;Tzu Chi Hosp, Dept Pathol, Hua Lien, Taiwan;China Med Coll, Dept Physiol, Sch Med, Taichung, Taiwan
日期:	1999
上傳時間:	2010-09-24 14:57:38 (UTC+8)
出版者:	P J D PUBLICATIONS LTD
摘要:	The objectives of this study are to describe the inhibitory effect of 9,10-anthraquinone 2-carboxylic acid (AQCA) on IgE-mediated passive cutaneous anaphylaxis (PCA) reaction, and the pharmacokinetics of AQCA. Pharmacodynamic assessments were performed at 0.5, 1 and 2 mg/kg (i.v.) and 5, 10 and 20 mg/kg (p.o) dose levels. In separate groups, pharmacokinetics were assessed at 5 mg/kg (i.v.) and 5, 10, and 20 mg/kg (p.o.) dose levels. Intravenous and oral administration of AQCA inhibited the PCA reaction in rats in a dose-dependent manner. The PCA-inhibitory activity of AQCA (20 mg/kg) lasted more than 12 hrs after oral administration. The oral bio-availability decreased with increasing dosage, from 96% (5 mg/kg) to 81% (10 and 20 mg/kg). The absorption after oral administration was prolonged with T-max values ranging from 1 to 6 h; while t(1/2) (4.8 - 16 h) values appeared to be comparable. These results suggest that AQCA has a potent and long acting anti-PCA activity. It is likely to be therapeutically useful in the treatment of asthma.
關聯:	RESEARCH COMMUNICATIONS IN MOLECULAR PATHOLOGY AND PHARMACOLOGY 105(1月2日):11-22
顯示於類別:	[醫學系] 期刊論文

文件中的檔案:

沒有與此文件相關的檔案.

在CMUR中所有的資料項目都受到原著作權保護.

TAIR相關文章

資料載入中.....